{"title": "PDF", "author": "PDF", "url": "https://www.samfyc.es/wp-content/uploads/2018/08/AlertaMayo2013.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Mayo 2013  \nSelecci\u00f3n realizada por Antonio Manteca Gonz\u00e1lez  \n \nANNALS OF INTERNAL MEDICINE  \n \nRaman G, Moorthy D, Hadar N, Dahabreh IJ, O'Donnell TF, Thaler DE, et al. Management strategies for \nasymptomatic carotid stenosis: a systematic review and meta -analysis. Ann Intern Med . 2013;  158:676 -685 [M,II]  \n23648949  R/C \nESTRATEGIAS DE MANEJO DE LA ESTENOSIS CAROT\u00cdDEA ASINTOM\u00c1TICA: REVISI\u00d3N SISTEM\u00c1TICA Y \nMETAAN\u00c1LISIS  \n \nMoyer VA; U.S. Preventive Services Task Force*. Vitamin D and calcium supplementation to prevent fractures in \nadults: U.S. Preventive Services Task Force re commendation statement. Ann Intern Med . 2013;  158:691 -696 [M,III]  \n23440163  R/C \nSUPLEMENTOS DE CALCIO Y VITAMINA D PARA PREVENIR FRACTURAS EN ADULTOS: DECLARACI\u00d3N DE \nRECOMENDACI\u00d3N DEL US PREVENTIVE SERVICES TASK FORCE  \n \nNestle M, Nesheim MC. To supplement or not to supplement: the U.S. Preventive Services Task Force \nrecommendations on calcium and vitamin D. Ann Intern Med . 2013;  158:701 -702 [M,III]  \n23440174  \nSUPLEMENTAR O NO SUPLEMENTAR: RECOMENDACIONES DEL US PREVENTICE SERVICES TASK \nFORCE SOBRE EL CALCIO Y LA VITAMINA D  \n \nKao D, Bucher Bartelson B, Khatri V, Dart R, Mehler PS, Katz D, et al. T rends in reporting methadone -associated \ncardiac arrhythmia, 1997 -2011: an analysis of registry data. Ann Intern Med . 2013;  158:735 -740 [T,II]  \n23689766  R/C \nTENDENCIAS E N LOS INFORMES SOBRE ARRITMIA CARDIACA ASOCIADA A METADONA, 1997 -2011: \nAN\u00c1LISIS DE DATOS DE LOS REGISTROS  \n \nO'Connor E, Gaynes BN, Burda BU, Soh C, Whitlock EP. Screening for and treatment of suicide risk relevant to \nprimary care: a systematic review for th e U.S. Preventive Services Task Force. Ann Intern Med . 2013;  158:741 -754 \n[M,II]  \n23609101  R/C \nCRIBAJE Y TRATAMIENTO DEL RIESGO RELEVANTE DE SUICIDIO EN ATENCI\u00d3N PRIMARIA: REVISI\u00d3N \nSISTEM\u00c1TICA PARA EL US PREVENTIVE SERVICES TASK FORCE  \n \nQaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College \nof Physicians*. Screening for prostate cancer: a guidance statement from t he Clinical Guidelines Committee of the \nAmerican College of Physicians. Ann Intern Med . 2013;  158:761 -769 [M,III]  \n23567643  R/C \nCRIBAJE DEL C\u00c1NCER DE PR\u00d3STATA: DECLARACI\u00d3N DE ORIENTACI\u00d3N DEL COMIT\u00c9 DE GU\u00cdAS CL\u00cdNICAS \nDEL AMERICAN COLLEGE OF PHYSICIANS  \n \nRepetto L, Abbatecola AM, Paolisso G. \"The older, the wiser\" in prostate cancer treatment choices? Ann Intern \nMed. 2013;  158:772 -773 [AO,I]  \n23689767  \n\u00bf\"LO M\u00c1S ANTIGUO, LO M\u00c1S SABIO\" EN LAS ELECCIONES DE TRATAMIENTO DEL C\u00c1NCER DE \nPR\u00d3STATA?  \n \nATENCION PRIMARIA  \n \nFern\u00e1ndez -Liz E \u00bfC\u00f3mo revisar la medicaci\u00f3n en los pacientes pluripatol\u00f3gicos? Aten Primaria . 2013;  45:233 -234 \n[AO,I]  \n23684377  \n\u00bfC\u00d3MO REVISAR LA MEDICACI\u00d3N EN LOS PACIENTES PLURIPATOL\u00d3GICOS?  \n \nGalv\u00e1n -Banqueri M, Gonz\u00e1lez -M\u00e9ndez AI, Alfaro -Lara ER, Nieto -Mart\u00edn MD, P\u00e9rez -Guerre ro C, Santos -Ramos B. \nEvaluaci\u00f3n de la adecuaci\u00f3n del tratamiento farmacol\u00f3gico en pacientes pluripatol\u00f3gicos.  Aten Primaria . 2013;  \n45:235 -243 [T,I]  \n23337466  R/C \nEVAL UACI\u00d3N DE LA ADECUACI\u00d3N DEL TRATAMIENTO FARMACOL\u00d3GICO EN PACIENTES \nPLURIPATOL\u00d3GICOS  \n Brenes FJ, Cozar JM, Esteban M, Fern\u00e1ndez -Pro A, Molero JM. Criterios de derivaci\u00f3n en incontinencia urinaria \npara atenci\u00f3n primaria. Aten Primaria . 2013;  45:263 -273 [R,II ] \n23623519  R/C \nCRITERIOS DE DERIVACI\u00d3N EN INCONTINENCIA URINARIA PARA ATENCI\u00d3N PRIMARIA  \n \nSegura A, Giner V. El consumo sanitario inapropiado y la trivializaci\u00f3n de la medicina. Aten Primaria . 2013;  45:274 -\n277 [AO,II]  \n23218832  R/C \nEL CONSUMO SANITARIO INAPROPIADO Y LA TRIVIALIZACI\u00d3N DE LA MEDICINA  \n \nBRITISH JO URNAL OF PSYCHIATRY  \n \nBaldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry . 2013;  202:396 -397 [AO,I]  \n23732933  R/C \nANTIDEPRESIVOS Y DISFUNCI\u00d3N SEXUAL  \n \nRajyaguru P, Cooper M. Role of dietary supplementation in attention -deficit hyperactivity disorder. Br J Psychiatry . \n2013;  202:398 -399 [AO,I]  \n23732934  R/C \nPAPEL DE LOS SUPLEMENTOS DIET\u00c9TICOS EN EL TRASTORNO DE HIPERACTIVIDAD Y D\u00c9FICIT DE \nATENCI\u00d3N  \n \nStrech D, Mertz M, Kn\u00fcppel H, Neitzke G, Schmidhuber M. The full spectrum of ethical issues in dementia care: \nsystematic qualitative  review. Br J Psychiatry . 2013;  202:400 -406 [M,II]  \n23732935  R/C \nESPECTRO COMPLETO DE ASPECTOS \u00c9TICOS DE LA ATENCI\u00d3N A LA DEMENCIA: REVISI\u00d3N \nSISTEM\u00c1TICA CUALITATIVA  \n \nBRITISH MEDICAL JOURNAL  \n \nReid IC. Are antidepressants overprescribed? No. BMJ . 2013;  346:f190 [AO,I]  \n23341567  \n\u00bfSE PRESCRIBEN EN EXCESO LOS ANTIDEPRESIVOS?  NO \n \nSpence D.  Are antidepressants overprescribed? Yes. BMJ . 2013;  346:f191 [AO,I]  \n23341568  \n\u00bfSE PRESCRIBEN EN EXCESO LOS ANTIDEPRESIVOS?  S\u00cd \n \nVickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Bj\u00f6rk T, Gerdtsson A, et al. Strategy for detection of prostate \ncancer based on relation between prostate specific antigen at age 40 -55 and long term risk of metastasis: case -\ncontrol study. BMJ. 2013;  346:f2023 [CC,II]  \n23596126  R/C \nESTRATEGIA PARA LA DETECCI\u00d3N DEL C\u00c1NCER DE PR\u00d3STATA BASADA EN LA RELACI\u00d3N ENTRE EL \nPSA A LOS 40 -55 A\u00d1OS DE EDAD Y EL RIESGO DE MET\u00c1STASIS A LARGO PLAZO: ESTUDIO DE CASO -\nCONTROL  \n \nToren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. Effect of dutasteride on clinical progression of benign \nprostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ. \n2013;  346:f2109 [EC,I]  \n23587564  R/C \nEFECTO DEL DUTASTERIDE SOBRE LA PROGRESI\u00d3N CL\u00cdNICA DE LA HIPERPLASIA BENIGNA DE \nPR\u00d3STATA EN HOMBRES ASINTOM\u00c1TICOS CON PR\u00d3STATA AGRANDADA: AN\u00c1LISIS POST HOC DEL \nESTUDIO REDUCE  \n \nEurich DT,  Simpson S, Senthilselvan A, Asche CV, Sandhu -Minhas JK, McAlister FA. Comparative safety and \neffectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;  \n346:f2267 [S,II]  \n23618722  R/C \nSEGURIDAD Y EFECTIVIDAD COMPARADAS DE LA SITAGLIPTINA EN PACIENTES CON DIABETES TIPO 2: \nESTUDIO RETROSPECTIVO DE COHORTE POBLACIONAL  \n \nMathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, et al. Cancer risk in 680 000 people \nexposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. \nBMJ. 2013;  346:f2360 ,[S,II]  \n23694687  R/C RIESGO DE C\u00c1NCER EN 680.000 PERSONAS EXPUESTAS A TAC EN LA NI\u00d1EZ Y ADOLESCENCIA: \nESTUDIO DE DATOS ENLAZADOS DE 11 MILLONES DE AUSTRALIANOS  \n \nLavigne E, Holowaty EJ, Pan SY, Villeneuve PJ, Johnson KC, Fergusson DA, et al. Breast cancer detection and \nsurvival among women with cosmetic breast implants: systematic review and meta -analysis of observational \nstudies. BMJ. 2013;  346:f2399 [M,II]  \n23637132  R/C \nDETECCI\u00d3N DE C\u00c1NCER DE MAMA Y SUPERVIVENCIA ENTRE MUJERES CON IMPLANTES DE MAMA \nCOSM\u00c9TICOS: REVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS DE ESTUDIOS OBSERVACIONALES  \n \nvan Vugt SF, Broekhuizen BD, Lammens C, Zuithoff NP, de Jong PA, Coenen S, et al; GRACE consortium. Use of \nserum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia \nin patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013;  346:f2450 [T,I]  \n23633005  R/C \nUSO DE LAS CONCENTRACIONES DE PCR S\u00c9RICO Y PROCALCITONINA ADEM\u00c1S DE LOS S\u00cdNTOMAS Y \nSIGNOS PARA PREDECIR NEUMON\u00cdA EN PACIENTES QUE ACUDEN CON TOS A LA ATENCI\u00d3N PRIMARIA: \nESTUDIO DIAGN\u00d3ST ICO \n \nSchouten HJ, Geersing GJ, Koek HL, Zuithoff NP, Janssen KJ, Douma RA, et al. Diagnostic accuracy of \nconventional or age adjusted D -dimer cut -off values in older patients with suspected venous thromboembolism: \nsystematic review and meta -analysis. BMJ. 2013;  346:f2492 [M,II]  \n23645857  R/C \nEXACTITUD DIAGN\u00d3STICA DE LOS VALORES DE CORTE DEL D\u00cdMERO D, TANTO CONVENCIONAL COMO \nAJUSTADO A LA EDAD, EN PACIENTES MAYORES CON SO SPECHA DE TROMBOEMBOLISMO VENOSO: \nREVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nEdmiston R, Mitchell C. Hearing loss in adults. BMJ. 2013;  346:f2496 [R,I]  \n23618723  \nP\u00c9RDIDA DE AUDICI\u00d3N EN ADULTOS  \n \nRoland M, Paddison C. Better management of patients with multimorbidity. BMJ. 2013;  346:f2510 [AO,I]  \n23641032  \nUN MEJOR MANEJO DE LOS PACIENTES CON PLURIMORBILIDAD  \n \nPilling S, Mayo -Wilson E, Mavranezouli I, Kew K, Taylor C, Clark DM; Guideline Development Group. Recognition, \nassessment and treatment of social anxiety disorder: summary of NICE guidance. BMJ. 2013;  346:f2541 [M,II]  \n2369 7669  \nRECONOCIMIENTO, VALORACI\u00d3N Y TRATAMIENTO DEL TRASTORNO DE ANSIEDAD SOCIAL: RESUMEN \nDE LA GU\u00cdA NICE  \n \nHippisley -Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic \nstroke in primary care and comparis on with other risk scores: a prospective open cohort study. BMJ. 2013;  \n346:f2573 [M,II]  \n23641033  R/C \nDERIVACI\u00d3N Y VALIDACI\u00d3N DE LA TABLA QSCORE PARA PREDECIR EL RIESGO  DE ICTUS ISQU\u00c9MICO \nEN ATENCI\u00d3N PRIMARIA Y COMPARACI\u00d3N CON OTRAS TABLAS DE RIESGO: ESTUDIO DE COHORTE \nPROSPECTIVA ABIERTA  \n \nCarter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients \ntreated with statins: popul ation based study. BMJ. 2013;  346:f2610 [S,II]  \n23704171  R/C \nRIESGO DE INCIDENCIA DE DIABETES ENTRE PACIENTES TRATADOS CON ESTATINAS: ESTUDIO \nPOBLACIONAL  \n \nDawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013;  346:f2634 [R,I]  \n23657180  \nACN\u00c9 VULGAR  \n \nDennis J, Ramsay T, Turgeon AF, Zarychanski  R. Helmet legislation and admissions to hospital for cycling related \nhead injuries in Canadian provinces and territories: interrupted time series analysis. BMJ. 2013;  346:f2674 [T,I]  \n23674137  R/C \nLEGISLACI\u00d3N SOBRE EL CASCO E INGRESOS EN EL HOSPITAL POR HERIDAS EN LA CABEZA \nRELACIONADAS CON EL CICLISMO EN LAS PROVINCIAS Y TERRITORIOS DE CANAD\u00c1: AN\u00c1LISIS DE \nSERIE TEMPORAL INTERRUMPIDA  \n Bird J, Biggs T, Thomas M, Salib  R. Adult acute rhinosinusitis. BMJ. 2013;  346:f2687 [R,I]  \n23667070  \nRINOSINUSITIS AGUDA EN EL ADULTO  \n \nStone S, Kontowski G, Gallagher R, Storr J, Teare  L. Keeping hand hygiene high on the patient safety agenda. \nBMJ. 2013;  346:f2699 [AO,I]  \n23635917  \nMANTENER LA HIGIENE DE MANOS EN LO ALTO DE LOS PLANES DE SEGURIDAD DEL PACIENTE   \n \nMoynihan R. The f uture of medicine lies in truly shared decision making. BMJ. 2013;  346:f2789 [AO,I]  \n23674138  \nEL FUTURO DE LA MEDICINA DESCANSA SOBRE LA VERDADERA TOMA DE DECISIONES COMPARTIDA  \n \nTiefer L, Witczak K , Heath I. A call to challenge the \"Selling of Sickness\". BMJ. 2013;  346:f2809 [AO,II]  \n23674139  \nLLAMAMIENTO A DESAFIAR A LA \"VENTA DE ENFERMEDADES\"  \n \nFields E, Chard J, Murphy MS, Richardson M; on behalf of the Guideline Development Group and technical team. \nAssessment and initial management of feverish illness in children younger than 5 years: summary of updated NICE \nguidance. BMJ. 2013;  346:f2866 [M,II]  \n23697671  \nVALORACI\u00d3N Y TRATAMIENTO INICIAL DE LA ENFERMEDAD FEBRIL EN LOS NI\u00d1OS DE MENOS DE 5 \nA\u00d1OS: RESUMEN DE LA GU\u00cdA NICE ACTUALIZADO  \n \nDavies E. Will MOOCs transform medicine? BMJ. 2013;  346:f2877 [AO,I]  \n\u00bfVAN A TRANSFORMAR LA MEDICINA LOS MOOC?  \n \nKennedy A, Bower P, Reeves D, Blakeman T, Bowen R, Chew -Graham C, et al; Salford National Institute for Health \nResearch Gastrointestinal programme Grant Research Group. Implementation of self management support for long \nterm conditions in routine pr imary care settings: cluster randomised controlled trial. BMJ. 2013;  346:f2882 [EC,II]  \n23670660  R/C \nPUESTA EN MARCHA DE LA AYUDA EN EL AUTOMANEJO DE ENFERMEDADES DE LARGA DURACI\u00d3N EN \nLOS DISPOSITIVOS HABITUALES DE ATENCI\u00d3N PRIMARIA: ENSAYO CONTROLADO ALEATORIZADO \nAGRUPADO  \n \nSugarman J. Implications of universal screening for HIV infection. BMJ. 2013;  346:f2957 [AO,I]  \n23657191  \nIMPLICACIONES DEL CRIBAJE UNIVERSAL DE LA INFECCI\u00d3N POR VIH  \n \nMaffulli N. Autologous blood products in musculoskeletal medicine. BMJ. 2013;  346:f2979 [AO,I]  \n23667073  \nPRODUCTOS AUT\u00d3LOGOS DE LA SANGRE EN LA MEDICINA OSTEOMUSCULAR  \n \nMcKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S et al. Telemonitoring based service redesign for the \nmanagement of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013;  346:f3030  [EC,I]  \n  R/C \nREDISE\u00d1O DEL SERVICIO BASADO EN LA TELEMONITORIZACI\u00d3N PARA EL MANEJO DE LA \nHIPERTENSI\u00d3N NO CONTROLADA: ENSAYO CONTROLADO ALEATORIZADO MULTIC\u00c9NTRICO  \n \nSegal J. Should we be reassured about sitaglipti n? BMJ. 2013;  346:f3051 [AO,I]  \n23674336  \n\u00bfDEBER\u00cdAMOS REASEGURARNOS RESPECTO A LA SITAGLIPTINA?  \n \nSodickson A. CT radiation risks coming into clearer focus. BMJ. 2013;  346:f3102 [AO,I]  \n23694689  \nTRAER LOS RIESGOS DE LA RADIACI\u00d3N POR TAC A LA CLARIDAD DE LOS FOCOS  \n \nMcCartney M. Antibiotics for back pain: hope or hype? BMJ. 2013;  346:f3122 [AO,I]  \n23674340  \nANTIBI\u00d3TICOS PARA EL DOLOR DE ESPALDA: \u00bfESPERANZA O EXAGERACI\u00d3N?  \n \nGupta K, Trautner BW. Diagnosis and management of recurrent urinary tract  \ninfections in non -pregnant women. BMJ. 2013;  346:f3140 [R,I]  \n23719637  DIAN\u00d3STICO Y MANEJO DE LAS INFECCIONES RECURRENTES DE V\u00cdAS URINARIAS EN MUJERES NO \nEMBARAZADAS  \n \nHuupponen R, Viikari J. Statins and the risk of developing diabetes. BMJ . 2013;  346:f3156 [AO ,I] \nESTATINAS Y RIESGO DE DESARROLLAR DIABETES  \n \nD'Souza S, Guptha S. Preventing admission of older people to hospital. BMJ. 2013;  346:f3186 [AO,I]  \n23690461  \nPREVENIR EL INGRESO DE LOS ANCIANOS EN EL HOSPITAL  \n \nSedgwick P. Statistical question: P values or confidence intervals? BMJ. 2013;  346:f3212 [AO,I]  \nPREGUNTA ESTAD\u00cdSTICA: \u00bfVALORES P O INTERVALOS DE CONFIANZA?  \n \nCANADIAN MEDICAL ASSOCIATION JOURNAL  \n \nFletcher J. Exemplary medicine: why doctors should practise what they preach. CMAJ . 2013;  185:635 [AO,I]  \n23670866  \nMEDICINA EJEMPLARIZANTE: \u00bfPOR QU\u00c9 LOS M\u00c9DICOS DEBER\u00cdAN PRACTICAR LO QUE PREDICAN?  \n \nGardam M, Lemieux C. Mandatory influenza vaccination? First we need a better vaccine. CMAJ . 2013;  185:639 -640 \n[AO,I]  \n23529962  \n\u00bfVACUNA ANTIGRIPAL OBLIGATORIA?  PRIMERO SE NECESITA UNA VACUNA MEJOR  \n \nGandell D, Straus SE, Bundookwala M, Tsui V, Alibhai SM. Treatment of constipation in older people. CMAJ . 2013;  \n185:663 -670 [R,I]  \n23359042  \nTRATAMIENTO DEL ESTRE\u00d1IMIENTO EN LAS PERSONAS MAYORES  \n \nKuwert P, Pietrzak RH, Glaesmer H. Trauma and posttraumatic stress disorder in older adults. CMAJ . 2013;  \n185:685 [R,I]  \n23339159  \nTRAUMA Y TRASTORNO DE ESTR\u00c9S POSTRAUM\u00c1TICO EN ANCIANOS  \n \nKoskenkorva T, Koivunen P, Koskela M, Niemela O, Kristo A, Alho OP. Short -term outcomes of tonsillectomy in \nadult patients with recurrent pharyngitis: a randomized controlled trial. CMAJ . 2013;  185:E331 -E336 [EC,II]  \n23549975  R/C \nRESULTADOS A CORTO PLAZO DE LA TONSILECTOM\u00cdA EN PACIENTES ADULTOS CON FARINGITIS \nRECURRENTE: ENSAYO CONTROLADO ALEATORIZADO  \n \nYoung JW, Juurlink DN. Tramadol . CMAJ . 2013;  185:E352 [R,I]  \n23509136  \nTRAMADOL  \n \nCIRCULATION  \n \nGold DR, Mittleman MA. New insights into pollution and the cardiovascular system: 2010 to 2012. Circulation . 2013;  \n127:1903 -1913 [R,II]  \n23648681  \nNUEVAS REFLEXIONES SOBRE CONTAMINACI\u00d3N Y SISTEMA CARDIOVASCULAR: 2010 A 2012  \n \nAnderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH , et al. Management of patients with atrial \nfibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations): a report of the \nAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation . 2013;  \n127:1916 -1926 [M,III]  \n23545139  \nMANEJO DE PACIENTES CON FIBRILACI\u00d3N AURICULAR (COMPILACI\u00d3N DE LAS RECOMENDACIONES \nACCF/AHA/ESC 2006 Y ACCF/AHA/HRS 2011): INFORME DEL ACC/AHA TASK FORCE SOBRE  GU\u00cdAS DE \nPR\u00c1CTICA CL\u00cdNICA  \n \nJackson R, Kerr A, Wells S. Vascular risk calculators: essential but flawed clinical tools? Circulation . 2013;  \n127:1929 -1931 [AO,I]  \n23580778  \nCALCULADORES DE RIESGO VASC ULAR: \u00bfHERRAMIENTAS CL\u00cdNICAS ESENCIALES PERO \nDEFECTUOSAS?   \nAllan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular \ndisease risk calculators. Circulation . 2013;  127:1948 -1956 [T,II]  \n23575355  R/C \nCONCORDANCIA ENTRE LOS CALCULADORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR  \n \nRutherford JD. Digital clubbing. Circulation . 2013;  127:1997 -1999 [AO,I]  \n23671180  \nDEDOS EN PALILLO DE TAMBOR  \n \nDIABETES CARE  \n \nArjona JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and safety of sitagliptin versus glipizide in  \npatients with type 2 diabetes and moderate -to-severe chronic renal insufficiency. Diabetes Care . 2013;  36:1067 -\n1073 [EC,I]  \n23248197  R/C \nEFICACIA Y SEGURIDAD DE LA SITAGLIPTINA FRENTE A LA GLIPIZIDA EN PACIENTES CON DIABETES \nTIPO 2 E INSUFICIENCIA RENAL CR\u00d3NICA DE MODERADA A GRAVE  \n \nRubin RR, Peyrot M, Gaussoin SA, Espeland MA, Williamson D, Faulconbridge LF, et al; Look AHEAD Research \nGroup. Four -year analysis of car diovascular disease risk factors, depression symptoms, and antidepressant \nmedicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes \nCare . 2013;  36:1088 -1094 [EC,II]  \n23359362  R/C \nAN\u00c1LISIS DE CUATRO A\u00d1OS DE FACTORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR, S\u00cdNTOMAS \nDE DEPRESI\u00d3N Y USO DE MEDICAMENTOS ANTIDEPRESIVOS EN EL ENSAYO CL\u00cdNICO LOOK AHEAD DE \nP\u00c9RDIDA DE PESO EN  LA DIABETES  \n \nMorrison F, Shubina M, Goldberg SI, Turchin A. Performance of primary care physicians and other providers on key \nprocess measures in the treatment of diabetes. Diabetes Care . 2013;  36:1147 -1152 [S,II]  \n23230095  R/C \nRENDIMIENTO DE LOS M\u00c9DICOS DE ATENCI\u00d3N PRIMARIA Y DE OTROS PROFESIONALES SOBRE \nMEDIDAS CLAVE DE PROCESO EN EL TRATAMIENTO DE LA DIABETES  \n \nTanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al; Japan Diabetes Complications Study \nGroup and the Japanese Elderly Diabetes Intervention Trial Group. Predicting macro - and microvascular \ncomplications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabete s \nIntervention Trial risk engine. Diabetes Care . 2013;  36:1193 -1199 [M,II]  \n23404305  R/C \nPREDECIR COMPLICACIONES MACRO Y MICROVASCULARES EN LA DIABETES TIPO 2: CALCULAD OR DE \nRIESGO DEL JAPAN DIABETES COMPLICATIONS STUDY/THE JAPANESE ELDERLY DIABETES \nINTERVENTION TRIAL  \n \nDanaei G, Garc\u00eda LA, Fernandez O, Hern\u00e1n MA. Statins and risk of diabetes: an analysis of electronic medical \nrecords to evaluate possible bias due to diff erential survival. Diabetes Care . 2013;  36:1236 -1240 [T,II]  \n23248196  R/C \nESTATINAS Y RIESGO DE DIABETES: AN\u00c1LISIS DE LAS HISTORIAS CL\u00cdNICAS ELECTR\u00d3NICAS PARA \nEVALUAR P OSIBLE SESGO DEBIDO A DIFERENCIAL DE SUPERVIVENCIA  \n \nReis JP, Hankinson AL, Loria CM, Lewis CE, Powell -Wiley T, Wei GS, et al. Duration of abdominal obesity \nbeginning in young adulthood and incident diabetes through middle age: the CARDIA study. Diabetes Ca re. 2013;  \n36:1241 -1247 [S,II]  \n23248193  R/C \nDURACI\u00d3N DEL COMIENZO DE LA OBESIDAD ABDOMINAL EN LA JUVENTUD E INCIDENCIA DE DIABETES \nDURANTE LA EDAD MEDIANA: ESTUDIO CARDIA  \n \nGerstein HC, Ambrosius WT, Danis R, Ismail -Beigi F, Cushman W, Calles J, et L; ACCORD Study Group. Diabetic \nretinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care . 2013;  \n36:1266 -1271 [EC,II]  \n23238658  R/C \nRETINOPAT\u00cdA DIAB\u00c9TICA, SU PROGRESI\u00d3N E INCIDENCIA DE ACONTECIMIENTOS CARDIOVASCULARES \nEN EL ENSAYO ACCORD  \n Jakicic JM, Egan CM, Fabricatore AN, Gaussoin SA, Glasser S P, Hesson LA, et al; Look AHEAD Research Group. \nFour-year change in cardiorespiratory fitness and influence on glycemic control in adults with type 2 diabetes in a \nrandomized trial: the Look AHEAD trial. Diabetes Care . 2013;  36:1297 -1303 [EC,II]  \n23223405  R/C \nCAMBIO EN CUATRO A\u00d1OS EN LA APTITUD CARDIORRESPIRATORIA E INFLUENCIA SOBRE EL CONTROL \nGLUC\u00c9MICO EN ADULTOS CON DIABETES TIPO 2 EN UN ENSAYO ALEATORIZADO: ENSAYO LOOK AHEAD  \n \nHong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al; SPREAD -DIMCAD Investigators. Effects of metformin versus \nglipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care . \n2013;  36:1304 -1311 [EC ,I] \n23230096  R/C \nEFECTOS DE LA METFORMINA FRENTE A LA GLIPIZIDA SOBRE LOS RESULTADOS CARDIOVASCULARES \nEN PACIENTES CON DIABETES TIPO 2 Y ENFERMEDAD ARTERIAL CORONARIA  \n \nTsur A, Feldman BS, Feldhammer I, Hoshen MB, Leibowitz G, Balicer RD. Decreased serum concentrations of 25 -\nhydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetes. \nDiabetes Care . 2013;  36:1361 -1367  [S,I] \n23393216  R/C \nLAS CONCENTRACIONES S\u00c9RICAS DISMINUIDAS DE 25 -HIDROXICOLECALCIFEROL SE ASOCIAN CON \nAUMENTO DEL RIESGO DE PROGRESI\u00d3N HACIA GLUCEMIA BASAL ALTERADA Y  DIABETES  \n \nSeaquist ER, Anderson J, Childs B, Cryer P, Dagogo -Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a \nworkgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care . 2013;  36:1384 -1395 \n[M,III]  \n23589542  R/C \nHIPOGLUCEMIA Y DIABETES: INFORME DE UN GRUPO DE TRABAJO DE LA AMERICAN   \nDIABETES ASSOCIATION Y LA ENDOCRINE SOCIETY  \n \nSong Y, Wang L, Pittas AG, Del Gobbo LC , Zhang C, Manson JE, et al. Blood 25 -hydroxy vitamin D levels and \nincident type 2 diabetes: a meta -analysis of prospective studies. Diabetes Care . 2013;  36:1422 -1428 [M,II]  \n23613602  R/C \nNIVELES SANGU\u00cdNEOS DE 25 -HIDROXI -VITAMINA D E INCIDENCIA DE DIABETES TIPO 2: METAAN\u00c1LISIS \nDE ESTUDIOS PROSPECTIVOS  \n \nLeal J, Hayes AJ, Gray AM, Holman RR, Clarke PM. Temporal validation of the UKPDS outcomes model using 10 -\nyear posttrial  monitoring data. Diabetes Care . 2013;  36:1541 -1546 [EC,II]  \n23275370  R/C \nVALIDACI\u00d3N TEMPORAL DEL MODELO DE RESULTADOS DEL UKPDS USANDO DATOS DE \nMONITORIZACI\u00d3N POST -ENSAYO A LOS 10 A\u00d1OS  \n \nPreis SR, Pencina MJ, Mann DM, D'Agostino RB Sr, Savage PJ, Fox CS. Early -adulthood cardiovascular disease \nrisk factor profiles among individuals with and without diabetes in the Framingham Heart study. Diabetes Care . \n2013;  36:1590 -1596 [S,II] \n23340887  R/C \nPERFILES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR EN LA VIDA ADULTA TEMPRANA ENTRE \nINDIVIDUOS CON Y SIN DIABETES EN EL ESTUDIO FRAMINGHAM HEART  \n \nKaton JG, Reiber GE, Nelson KM. Peripheral neuropathy defined by monofilament insensitivity and diabetes status: \nNHANES 1999 -2004. Diabetes Care . 2013;  36:1604 -1606 [T,II]  \n23275365  R/C \nNEUROPAT\u00cdA PERIF\u00c9RICA DEFINIDA POR LA INSENSIBILIDAD AL MONOFILAMENTO EN EL ESTADO DE \nDIABETES: NHANES 1999 -2004  \n \nTODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical  \ntrial. Diabetes Care . 2013;  36:1735 -1741 [EC,II]  \n23704672  R/C \nR\u00c1PIDO AUMENTO DE LA HIPERTENSI\u00d3N Y LA NEFROPAT\u00cdA EN LOS J\u00d3VENES CON DIABETES TIPO 2: \nENSAYO CL\u00cdNICO TOD AY \n \nLinder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. \nDiabetes Care . 2013;  36:1775 -1776 [AO,I]  \n23704678  \nESTUDIO TODAY: PERSPECTIVA DE LOS NIH  SOBRE SUS IMPLICACIONES PARA LA INVESTIGACI\u00d3N  \n \nDRUGS   \nKeating GM. Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of \ndiabetes mellitus. Drugs . 2013;  73:575 -593 [R,II]  \n23620200   R/C \nINSULINA DEGLUDEC E INSULINA DEGLUDEC/INSULINA ASPART: REVISI\u00d3N DE SU USO EN EL \nTRATAMIENTO DE LA DIABETES MELLITUS  \n \nCarter NJ, Plosker GL. Rivaroxaban : a review of its use in the prevention of stroke and systemic embolism in \npatients with atrial fibrillation. Drugs . 2013;  73:715 -739 [R,II]  \n23677801   R/C \nRIVAROXAB\u00c1N:  REVISI\u00d3N DE SU USO EN LA PREVENCI\u00d3N DEL ICTUS Y EL EMBOLISMO SIST\u00c9MICO EN \nPACIENTES CON FIBRILACI\u00d3N AURICULAR  \n \nCarter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic \nobstructive pulmonary disease. Drugs . 2013;  73:741 -753 [R,II]  \n23677802   R/C \nBROMURO DE GLUCOPIRRONIO INHALADO: REVISI\u00d3N DE SU USO EN PACIENTES CON EPOC DE \nMODERADO A GRAVE  \n \nEUROPEAN HEART JOURNAL  \n \nChapman MJ, Giral P, Barter PJ. The conundrum of C -reactive protein as a risk marker for cardiovascular risk \nassessment: insight from EPIC -Norfolk and JUPITER. Eur Heart J . 2013;  34:1318 -1320 [AO,I]  \n23482520  \nEL ENIGMA DE LA PROTE\u00cdNA C REACTIVA COMO MARCADOR DE RIESGO EN LA VALORACI\u00d3N DEL \nRIESGO CARDIOVASCULAR: REFLEXI\u00d3N SOBRE EPIC -NORFOLK Y JUPITER  \n \nSondermeijer BM, Boekholdt SM, Rana JS, Kastelein JJ, Wareham NJ, Khaw KT . Clinical implications of JUPITER \nin a contemporary European population: the EPIC -Norfolk prospective population study. Eur Heart J . 2013;  \n34:1350 -1357 [S,II]  \n23449857  R/C \nIMPLICACIONES CL\u00cdNICAS DEL JUPITER EN UNA POBLACI\u00d3N EUROPEA CONTEMPOR\u00c1NEA: ESTUDIO \nPROSPECTIVO DE POBLACI\u00d3N EPIC -NORFOLK  \n \nZittermann A, Kuhn J, Dreier J, Knabbe C, Gummert JF, B\u00f6rgermann J. Vitamin D status and the risk of ma jor \nadverse cardiac and cerebrovascular events in cardiac surgery. Eur Heart J . 2013;  34:1358 -1364 [S,I]  \n23315905  R/C \nESTADO DE VITAMINA D Y RIESGO DE ACONTECIMIENTOS ADVERSOS IMPORTANTES CARDIACOS Y \nCEREBROVASCULARES EN CIRUG\u00cdA CARDIACA  \n \nTomson J, Emberson J, Hill M, Gordon A, Armitage J, Shipley M, et al. Vitamin D and risk of death from vascular \nand non -vascular causes in the Whitehall study and meta -analyses of 12 0 00 deaths. Eur Heart J . 2013;  34:1365 -\n1374 [M,II]  \n23257953  R/C \nVITAMINA D Y RIESGO DE MUERTE POR CAUSAS VASCULARES Y NO VASCULARES EN EL ESTUDIO \nWHITEHALL Y METAAN\u00c1LISIS DE 12.000 MUERTES  \n \nBraunwald E. Chronic heart failure: a look through the rear view mirror. Eur Heart J . 2013;  34:1391 -1392 [AO,I]  \n23103661  \nINSUFICIENCIA CARDIACA CR\u00d3NICA: MIRADA POR EL RETROVISOR  \n \nPocock SJ, Ariti CA, McMurray JJ, Maggioni A, K\u00f8ber L, Squire IB, et al; Meta -Analysis Global Group in Chronic \nHeart Failure (MAGGIC). Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. \nEur Heart J . 2013;  34:1404 -1413 [M,II]  \n23095984  R/C \nPREDECIR LA SUPERVIVENCIA EN LA INSUFICIENCIA CARDIACA: TABLA DE RIESGO BASADA EN 39.372 \nPACIENTES DE 30 ESTUDIOS  \n \nvan Veldhuise n DJ, Van Gelder IC, Ahmed A, Gheorghiade M. Digoxin for patients with atrial fibrillation and heart \nfailure: paradise lost or not? Eur Heart J . 2013;  34:1468 -1470 [AO,I]  \n23324547  \nDIGOXINA EN PACIENTES CON FIBRILACI\u00d3N AURICULAR E INSUFICIENCIA CARDIACA: \u00bfPARA\u00cdSO \nPERDIDO O NO?  \n Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the \nAtlantic: a comparison of the current recommendations o f the European Society of Cardiology/European Heart \nRhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology \nFoundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur \nHeart J . 2013;  34:1471 -1474 [M,III]  \n23355653  \nGU\u00cdAS SOBRE FIBRILACI\u00d3N AURICULAR A TRAV\u00c9S DEL ATL\u00c1NTICO: COMPARACI\u00d3N DE LAS \nRECOMENDACIONES ACTUALES DE LAS EUROPEAN SOCIETY OF CARDIOLOGY/EUROPEA N HEART \nRHYTHM ASSOCIATION/EUROPEAN ASSOCIATION OF CARDIOTHORACIC SURGEONS, LAS AMERICAN \nCOLLEGE OF CARDIOLOGY FOUNDATION/AMERICAN HEART ASSOCIATION/HEART RHYTHM SOCIETY, Y \nLA CANADIAN CARDIOVASCULAR SOCIETY  \n \nHijazi Z, Oldgren J, Siegbahn A, Granger CB, Wa llentin L. Biomarkers in atrial fibrillation: a clinical review. Eur \nHeart . J 2013;  34:1475 -1480 [R,I]  \n23386711  R/C \nBIOMARCADORES EN LA FIBRILACI\u00d3N AURICULAR: REVISI\u00d3N  CL\u00cdNICA  \n \nWhitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients \ntaking digoxin --analysis from the AFFIRM study. Eur Heart J . 2013;  34:1481 -1488 [S,II]  \n23186806  R/C \nAUMENTO DE MORTALIDAD ENTRE PACIENTES QUE TOMAN DIGOXINA -- AN\u00c1LISIS DEL ESTUDIO AFFIRM  \n \nGheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, et al. Lack of evidence of \nincrease d mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity -matched \nanalysis of the AFFIRM trial. Eur Heart J . 2013;  34:1489 -1497 [S,II]  \n23592708  R/C \nFALTA DE PRUEBAS DE AUMENTO DE MORTALIDAD ENTRE PACIENTES CON FIBRILACI\u00d3N AURICULAR \nQUE TOMAN DIGOXINA: HALLAZGOS DEL AN\u00c1LISIS EMPAREJADO DE TENDENCIA POST -HOC DEL \nENSAYO AFFIRM  \n \nConnolly SJ, Eikelboom J, Dorian P, Hohnloser  SH, Gretler DD, Sinha U, et al. Betrixaban compared with warfarin \nin patients with atrial fibrillation: results of a phase 2, randomized, dose -ranging study (Explore -Xa). Eur Heart J . \n2013;  34:1498 -1505 [EC,II]  \n23487517  R/C \nBETRIXABAN COMPARADO CON WARFARINA EN PACIENTES CON FIBRILACI\u00d3N AURICULAR: \nRESULTADOS DE UN ESTUDIO DE AMPLITUD DE DOSIS, ALEATORIZADO, EN FASE 2 (EXPLORE -XA) \n \nFAMILY MEDICINE  \n \nKruse RL, Olsberg JE, Oliver DP, Shigaki CL, Vetter -Smith MJ, Lemaster JW. Patient -provider communication \nabout diabetes self -care activities. Fam Med . 2013;  45:319 -322 [C,I]  \n23681682   R/C \nCOMUNICACI\u00d3N ENTRE EL PACIENTE Y EL PROFESIONAL SOBRE LAS ACTIVIDADES DE AUTOCUIDADO \nEN LA DIABETES  \n \nYoung RA, Bayles B, Benold  TB, Hill JH, Kumar KA, Burge S. Family physicians' perceptions on how they deliver \ncost-effective care: a qualitative study from the Residency Research Network of Texas (RRNeT). Fam Med . 2013;  \n45:311 -318 [C,I]  \n23681681   R/C \nPERCEPCIONES DE LOS M\u00c9DICOS DE FAMILIA DE C\u00d3MO PROPORCIONAN UNA ATENCI\u00d3N RENTABLE: \nESTUDIO CUALITATIVO DE LA RRNeT  \n \nDai H, Fang L, Malouin RA, Huang L, Yokosawa KE, Liu G. Family medicine training i n China. Fam Med . 2013;  \n45:341 -344 [R,I]  \n23681686  R/C \nFORMACI\u00d3N EN MEDICINA DE FAMILIA EN CHINA  \n \nScherger J. The inherent cost -effectiveness of family physicians. Fam Med. 2013;  45:309 -310 [AO,II]  \n23681680   \nLA RENTABILIDAD INHERENTE DE LOS M\u00c9DICOS DE FAMILIA  \n \nGACETA SANITARIA  \n \nBenavides FG, Ruiz -For\u00e8s N, Delcl\u00f3s J, Domingo -Salvany  A. Consumo de alcohol y otras drogas en el medio \nlaboral en Espa\u00f1a. Gac Sanit . 2013;  27:248 -253 [T,I]  22840438  R/C \nCONSUMO DE ALCOHOL Y OTRAS DROGAS EN EL MEDIO LABORAL EN ESPA\u00d1A  \n \nOrt\u00fan V. Las encrucijadas de la atenci\u00f3n primaria. Gac Sanit . 2013;  27:193 -195 [AO,II]  \n23578523  \nLAS ENCRUCIJADAS DE LA ATENCI\u00d3N PRIMARIA  \n \nHoffmann R, Plug I, Khoshaba B, McKee M , Mackenbach JP; AMIEHS working group. Mortalidad tratable revisada: \nel estudio AMIEHS. Gac Sanit . 2013;  27:199 -206 [T,II]  \n23207428  R/C \nMORTALIDAD TRATABLE REVISADA: E L ESTUDIO AMIEHS  \n \nRom\u00e1n B, Ribas L, Ngo J, Serra L. Validaci\u00f3n en poblaci\u00f3n catalana del cuestionario internacional de actividad \nf\u00edsica. Gac Sanit . 2013;  27:254 -257 [T,I]  \n23103093  R/C \nVALIDACI\u00d3N EN POBLACI\u00d3N CATALANA DEL CUESTIONARIO INTERNACIONAL DE ACTIVIDAD F\u00cdSICA  \n \nFuentes -Garc\u00eda A, S\u00e1nchez H, Lera L, Cea X, Albala C. Desigualdades socioecon\u00f3micas en el proceso de \ndiscapacidad en una cohorte de adultos mayores de Santiago de Chile. Gac Sanit . 2013;  27:226 -232 [S,II]  \n23291031  R/C \nDESIGUALDADES SOCIOECON\u00d3MICAS EN EL PROCESO DE DISCAPACIDAD EN UNA COHORTE DE \nADULTOS MAY ORES DE SANTIAGO DE CHILE  \n \nBlanco A, Urbanos R, Thuissard IJ. Evoluci\u00f3n de la prestaci\u00f3n real media en Espa\u00f1a por edad y sexo (1998 -2008) \ny su repercusi\u00f3n en las proyecciones de gasto sanitario p\u00fablico. Gac Sanit . 2013;  27:220 -225 [CE,II]  \n23140979  R/C \nEVOLUCI\u00d3N DE LA PRESTACI\u00d3N REAL MEDIA EN ESPA\u00d1A POR EDAD Y SEXO (1998 -2008) Y SU \nREPERCUSI\u00d3N EN LAS PROYECCIONES DE GASTO SANITARIO P\u00daBLICO  \n \nAller MB, Vargas I, Waibel S, Coderch -Lassaletta J, S\u00e1nchez -P\u00e9rez I, Llopart JR, et al. Factores asociados a la \ncontinuidad asistencial entre atenci\u00f3n primaria y atenci\u00f3n secundaria ambulatoria experimentada por los usuarios \nen el sistema de salud catal\u00e1n. Gac Sanit . 2013;  27:207 -213 [T,I] \n22981418  R/C \nFACTORES ASOCIADOS A LA CONTINUIDAD ASISTENCIAL ENTRE ATENCI\u00d3N PRIMARIA Y ATENCI\u00d3N \nSECUNDARIA AMBULATORIA EXPERIMENTADA POR LOS USUARIOS EN EL SISTE MA DE SALUD CATAL\u00c1N  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nGossett DR, Kiley JW, Hammond C. Contraception is a fundamental primary care service. JAMA 2013;309:1997 -\n1998 [AO,I]  \n23677310  \nLA ANTICONCEPCI\u00d3N ES UN SERVICIO FUNDAMENTAL DE ATENCI\u00d3N PRIMARIA  \n \nAge-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega -3 fatty acids for age -related \nmacular degene ration: the Age -Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA . 2013;  \n309:2005 -2015 [EC,I]  \n23644932  R/C \nLUTE\u00cdNA + ZEAXANTINA Y \u00c1CIDOS GRASOS OMEGA 3 EN LA DEGENERACI\u00d3N MACULA R RELACIONADA \nCON LA EDAD: ENSAYO CL\u00cdNICO ALEATORIZADO AREDS2  \n \nJAMA INTERNAL MEDICINE  \n \nWidera E. What's to blame for falls and fractures? Poor sleep or the sleeping medication?: comment on \n\"Nonbenzodiazepine  sleep medication use and hip fractures in nursing home residents\" JAMA Intern Med . 2013:  1-\n2 [Epub ahead of print] [AO,I]  \n23459766  \n\u00bfA QU\u00c9 HAY QUE ECHARLE LA CULPA DE LAS CA\u00cdDAS Y FRACTURAS?  \u00bfAL SUE\u00d1O DE MALA CALIDAD O \nA LA MEDICACI\u00d3N PARA DORMIR?: COMENTARIO SOBRE \"USO DE MEDICACI\u00d3N PARA DORMIR NO \nBENZODIAZEP\u00cdNICA Y FRACTURAS DE CADERA EN RESIDENCIAS DE ANCIANOS\"  \n \nLautenschlager NT, Cox KL. Can participation in mental and physical activity protec t cognition in old age? Comment \non \"The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older \nadults\" JAMA Intern Med . 2013:  1-2 [Epub ahead of print] [AO,I]  \n23545757  \u00bfPUEDE LA PARTICIPACI\u00d3N EN ACTIVIDADES MENTALES Y F\u00cdSICAS PROTEGER LA COGNICI\u00d3N EN LOS \nANCIANOS?  COMENTARIO SOBRE \"ENSAYO MAX: ENSAYO CONTROLADO ALEATORIZADO PARA \nREFORZAR LA FUNCI\u00d3N COGNITIVA EN ANCIANOS\"  \n \nBerry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home \nresidents. JAMA Intern Med . 2013:1 -8 [Epub ahead of print][CC,I]  \n23460413  R/C \nUSO DE MEDICACI\u00d3N PARA DORMIR NO BENZODIAZEP\u00cdNICA Y FRACTURAS DE CADERA EN \nRESIDENCIAS DE ANCIANOS  \n \nBarnes DE, Santos -Modesitt W, Poelke G, Kramer AF, Castro C, Middleton LE, et al. The Mental Activity and \neXercise (MAX) trial: a randomized controlled trial to  enhance cognitive function in older adults. JAMA Intern Med . \n2013:  1-8 [Epub ahead of print][EC,I]  \n23545598  R/C \nENSAYO MAX: ENSAYO CONTROLADO ALEATORIZADO PARA REFORZAR LA FUNCI\u00d3N COGNITIVA EN \nANCIANOS  \n \nKerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, et al; for the Breast Cancer Surveillance \nConsortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone  \ntherapy. JAMA Intern Med . 2013: 1-10 [Epub ahead of print][S,I]  \n23552817  R/C \nRESULTADOS DE LA MAMOGRAF\u00cdA DE CRIBAJE POR FRECUENCIA, DENSIDAD MAMARIA Y TERAPIA \nHORMONA L POSTMENOP\u00c1USICA  \n \nJAMA PSYCHIATRY  \n \nCinciripini PM, Robinson JD, Karam -Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and \nbupropion  sustained -release use plus intensive smoking cessation counseling on prolonged abstinence from \nsmoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry . 2013;  \n70:522 -533 [EC,I]  \n23536105  R/C \nEFECTOS DEL USO DE LA VARENICLINA Y EL BUPROPION DE LIBERACI\u00d3N SOSTENIDA M\u00c1S CONSEJO \nINTENSIVO SOBRE ABANDONO TAB\u00c1QUICO SOBRE LA ABSTINENCIA TAB\u00c1QUICA PROLONGADA Y \nSOBRE LA DEPRESI\u00d3N, AF ECTIVIDAD NEGATIVA Y OTROS S\u00cdNTOMAS DE LA RETIRADA DE LA NICOTINA  \n \nMEDICINA CLINICA  \n \nPascual -Figal DA. Amplitud de distribuci\u00f3n eritrocitaria, mucha m\u00e1s informaci\u00f3n con solo mirar el hemograma. Med \nClin (Barc) . 2013;  140:449 -450 [AO,I ] \n23332623  \nAMPLITUD DE DISTRIBUCI\u00d3N ERITROCITARIA, MUCHA M\u00c1S INFORMACI\u00d3N CON SOLO MIRAR EL \nHEMOGRAMA  \n \nG\u00f3mez -Vaquero C, Roig -Vilaseca D, Bianchi M, Santo P, Narv\u00e1ez J, Nolla JM. Evaluaci\u00f3n de una p ropuesta de \ncriterios de indicaci\u00f3n de densitometr\u00eda \u00f3sea en mujeres posmenop\u00e1usicas espa\u00f1olas basados en la herramienta \nFRAX \u00ae. Med Clin (Barc) . 2013;  140:439 -443 [T,I]  \n22578993  R/C \nEVALUACI\u00d3N DE UNA PROPUESTA DE CRITERIOS DE INDICACI\u00d3N DE DENSITOMETR\u00cdA \u00d3SEA EN \nMUJERES POSMENOP\u00c1USICAS ESPA\u00d1OLAS BASADOS EN LA HERRAMIENTA FRAX \u00ae  \n \nRuiz F, Castellano Mdel M, Aparisi  F. Papel de la radiolog\u00eda intervencionista en el diagn\u00f3stico y tratamiento de la \ncolumna vertebral dolorosa. Med Clin (Barc) . 2013;  140:458 -465 [R,I]  \n23177315  R/C \nPAPEL DE LA RADIOLOG\u00cdA INTERVENCIONISTA EN EL DIAGN\u00d3STICO Y TRATAMIENTO DE LA COLUMNA \nVERTEBRAL DOLOROSA  \n \nOlivares M, Santas E, Mi\u00f1ana G, Palau P, Merlos P, Sanchis J et al. Amplitud de distribuci\u00f3n eritrocitaria  y riesgo \nde mortalidad en pacientes con insuficiencia cardiaca aguda. Med Clin (Barc) . 2013;  140:433 -438 [T,I]  \n23337456  R/C \nAMPLITUD DE DISTRIBUCI\u00d3N ERITROCITARIA Y R IESGO DE MORTALIDAD EN PACIENTES CON \nINSUFICIENCIA CARDIACA AGUDA  \n \nTHE LANCET  \n Hepatitis C in the USA and Europe: two problems, one solution. Lancet . 2013;  381:1688 [AO,I]  \n23683614  \nHEPATITIS C EN EE UU Y EUROPA: DOS PROBLEMAS, UNA SOLUCI\u00d3N  \n \nVictora CG, Barros FC. Participatory women's groups: ready for prime time? Lancet . 2013;  381:1693 -1694 [AO,I]  \n23683618  \nGRUPOS DE PARTICIPACI\u00d3N DE MUJERES: \u00bfPREPARADOS PARA LA M\u00c1XIMA AUDIENCIA?  \n \nHawkes S, Buse K. Gender and global health: evidence, policy, and inconvenient truths. Lancet . 2013;  381:1783 -\n1787  [AO,I]  \n23683645  \nG\u00c9NERO SEXUAL Y SALUD MUNDIAL: EVIDENCIAS, POL\u00cdTICA Y VERDADES INCONVENIENTES  \n \nTHE NEW ENGLAND JOURNAL OF MEDICINE  \n \nBlumenthal D, Abrams MK. Putting aside preconceptions --time for dialogue among primary care clinicians. N Engl J \nMed. 2013;  368:1933 -1934 [AO,I]  \n23675662  \nPONER A UN LADO LOS PREJUICIOS --HORA DE DI ALOGAR ENTRE LOS CL\u00cdNICOS DE ATENCI\u00d3N \nPRIMARIA  \n \nUyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med . 2013;  \n368:1862 -1864 [AO,I]  \n23577629  \nPREOCUPACIONES MUNDIALES RESPECTO A LAS INFECCIONES POR EL NUEVO VIRUS DE LA GRIPE A \n(H7N9)  \n \nFrieden TR. Government's role in protecting health and safety. N Engl J Med . 2013;  368:1857 -1859 [AO,I]  \n23593978  \nEL PAPEL DEL GOBIERNO EN LA PROTECCI\u00d3N DE LA SALUD Y EN LA SEGURIDAD  \n \nDrenth JP. HCV treatment --no more room for interferonologists? N Engl J Med . 2013;  368:1931 -1932 [AO,I]  \n23607592  \nTRATAMIENTO DEL VIRUS DE LA HEPATITIS C \u00bfYA NO HAY SITIO PARA LOS INTERFERON\u00d3LOGOS?  \n \nGao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian -origin influenza A (H7N9) \nvirus. N Engl J Med . 2013;  368:1888 -1897 [T,II]  \n23577628  R/C \nINFECCI\u00d3N HUMANA CON UN NUEVO VIRUS DE LA GRIPE A (H7N9) DE ORIGEN AVIAR  \n \nDonelan K, DesRoches CM, Dittus RS, Buerhaus P. Perspectives of physicians and nur se practitioners on primary \ncare practice. N Engl J Med . 2013;  368:1898 -1906 [T,I]  \n23675658  R/C \nPERSPECTIVAS DE M\u00c9DICOS Y ENFERMERAS SOBRE LA PR\u00c1CTICA DE LA ATENCI\u00d3N P RIMARIA  \n \nRosenthal MB, Mello MM. Sunlight as disinfectant --new rules on disclosure of industry payments to physicians. N \nEngl J Med . 2013;  368:2052 -2054 [AO,I]  \n23718162  \nLA LUZ DEL SOL COMO DESINFE CTANTE -- NUEVAS REGLAS SOBRE LA DIVULGACI\u00d3N DE LOS PAGOS \nDE LA INDUSTRIA A LOS M\u00c9DICOS  \n \nLiang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med . 2013;  368:1907 -\n1917 [R,II]  \n23675659  \nTERAPIAS ACTUALES Y FUTURAS PARA LA INFECCI\u00d3N POR EL VIRUS DE LA HEPATITIS C  \n \nIglehart JK. Expanding the role of advanced nurse practitioners --risks and rewards. N Engl J Med . 2013;  368:193 5-\n1941 [AO,I]  \n23675663  \nAMPLIAR EL PAPEL DE LAS ENFERMERAS AVANZADAS -- RIESGOS Y RECOMPENSAS  \n \n ANNALS OF INTERNAL MEDICINE  \n \nS23609101  \nPrimary care -feasible screening tools might help to identify some adults at increased risk for suicide but have limited \nability to detect suicide risk in adolescents. Psychotherapy may reduce suicide attempts in some high -risk adults, \nbut effective interventions for high -risk adolescents are not yet proven.  \nS2356764 3  \nGUIDANCE STATEMENT 1: ACP recommends that clinicians inform men between the age of 50 and 69 years \nabout the limited potential benefits and substantial harms of screening for prostate cancer. ACP recommends that \nclinicians base the decision to screen fo r prostate cancer using the prostate -specific antigen test on the risk for \nprostate cancer, a discussion of the benefits and harms of screening, the patient's general health and life \nexpectancy, and patient preferences. ACP recommends that clinicians shoul d not screen for prostate cancer using \nthe prostate -specific antigen test in patients who do not express a clear preference for screening. GUIDANCE \nSTATEMENT 2: ACP recommends that clinicians should not screen for prostate cancer using the prostate -specifi c \nantigen test in average -risk men under the age of 50 years, men over the age of 69 years, or men with a life \nexpectancy of less than 10 to 15 years.  \nS23689766  \nSince 2002, reports to FAERS of methadone -associated arrhythmia have increased substantially a nd are \ndisproportionately represented relative to other events with the drug. Coadministration of methadone with \nantiretrovirals in patients with HIV may pose particular risk.  \nS23440163  \nThe USPSTF concludes that the current evidence is insufficient to ass ess the balance of the benefits and harms of \ncombined vitamin D and calcium supplementation for the primary prevention of fractures in premenopausal women \nor in men. (I statement)The USPSTF concludes that the current evidence is insufficient to assess the balance of the \nbenefits and harms of daily supplementation with greater than 400 IU of vitamin D3 and greater than 1000 mg of \ncalcium for the primary prevention of fractures in noninstitutionalized postmenopausal women. (I statement)The \nUSPSTF recommends a gainst daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of \ncalcium for the primary prevention of fractures in noninstitutionalized postmenopausal women. (D recommendation).  \nS23648949  \nFuture RCTs of asymptomatic carotid artery st enosis should explore whether revascularization interventions provide \nbenefit to patients treated by best -available medical therapy.  \n \nATENCION PRIMARIA  \n \nS23623519  \nA pesar de la elevada incidencia de incontinencia urinaria (IU) existe una escasa sensibilizaci\u00f3n de los \nprofesionales sanitarios hacia esta afecci\u00f3n, que no es grave, pero que s\u00ed autolimita de forma importante la vida de \nlas personas que la presentan. Las  sociedades cient\u00edficas de Atenci\u00f3n Primaria (Sociedad Espa\u00f1ola de M\u00e9dicos de \nAtenci\u00f3n Primaria [SEMERGEN], Sociedad Espa\u00f1ola de M\u00e9dicos Generales y de Familia [SEMG], Sociedad \nEspa\u00f1ola de Medicina de Familia y Comunitaria [semFYC]) y la Asociaci\u00f3n Espa\u00f1ol a de Urolog\u00eda [AEU]) han \nelaborado este documento de consenso con los objetivos de sensibilizar al m\u00e9dico de atenci\u00f3n primaria y ayudarle \na la evaluaci\u00f3n diagn\u00f3stica, tratamiento y derivaci\u00f3n al especialista de la IU. El primer objetivo desde atenci\u00f3n \nprimaria (AP) debe ser la detecci\u00f3n de la IU, por lo que se recomienda realizar un cribado oportunista al menos, \nuna vez a lo largo de la vida en mujeres asintom\u00e1ticas > 40 a\u00f1os y en varones asintom\u00e1ticos > 55 a\u00f1os. En la \nevaluaci\u00f3n diagn\u00f3stica, basada en la a namnesis y la exploraci\u00f3n f\u00edsica, se deber\u00e1 determinar el tipo y gravedad de \nla IU con el objetivo de derivar al especialista los casos de IU complicada. Con excepci\u00f3n de la vejiga hiperactiva \n(VH), el tratamiento conservador no farmacol\u00f3gico constituye el  abordaje principal de la IU no complicada, tanto en \nmujeres como en varones. En la IU de urgencia/VH (IUU/VH), los antimuscar\u00ednicos son los \u00fanicos f\u00e1rmacos que \nhan demostrado eficacia y seguridad. En el caso de los varones con s\u00edntomas mixtos, excluyendo los casos de \nobstrucci\u00f3n severa, se debe optar por un tratamiento combinado de alfa -bloqueantes y antimuscar\u00ednicos.  \nS23218832  \nUno de los problemas de nuestro sistema sanitario es el consumo inapropiado cuyas consecuencias m\u00e1s notorias \nson el despilfarro d e recursos y la iatrogenia que no est\u00e1 justificada por la expectativa de ning\u00fan beneficio en \nt\u00e9rminos de salud. Entre las posibles causas del consumo inadecuado se destaca la banalizaci\u00f3n de la medicina, \nque conlleva la p\u00e9rdida de respeto y la ausencia de miramientos y por eso facilita cuando no estimula la temeridad \nen el consumo. Una temeridad de la que son responsables tanto pacientes como sanitarios y seguramente todav\u00eda \nm\u00e1s gestores y pol\u00edticos. Sin una efectiva emancipaci\u00f3n que lleve a los usuarios y ciudadanos a controlar los \ndeterminantes de su salud no parece posible disminuir el consumo inapropiado ni la iatrogenia asociada.  \nS23337466  \nEl gran n\u00famero de inadecuaciones detectadas pone de manifiesto la importancia de evaluar la adecuaci\u00f3n del \ntratami ento farmacol\u00f3gico en el paciente pluripatol\u00f3gico. Para ello es recomendable utilizar una estrategia de \nintervenci\u00f3n farmac\u00e9utica combinada que incluya tanto un m\u00e9todo impl\u00edcito como un m\u00e9todo expl\u00edcito.  \n \nBRITISH JOURNAL OF PSYCHIATRY  \n S23732933  \nDepressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction \nbut the findings of randomised placebo -controlled trials demonstrate that antidepressant drugs can be associated \nwith the development or worsenin g of sexual dysfunction. Sexual difficulties during antidepressant treatment often \nresolve as depression lifts but may persist over long periods, and can reduce self -esteem and affect mood and \nrelationships adversely. Sexual dysfunction during antidepressa nt treatment is typically associated with many \npossible causes, but the risk of dysfunction varies with differing antidepressants, and should be considered when \nselecting an antidepressant.  \nS23732934  \nDietary constituents have been increasingly researched as both potential aetiological factors and interventions for \nattention -deficit hyperactivity disorder (ADHD) symptoms. Although the involvement of dietary factors in ADHD is \nbiologically plausible, the  literature to date does not indicate causality and there are no grounds yet for the routine \nrecommendation of dietary manipulation in ADHD.  \nS23732935  \nThe systematically derived spectrum of ethical issues in clinical dementia care presented in this paper c an be used \nas training material for healthcare professionals, students and the public for raising awareness and understanding of \nthe complexity of ethical issues in dementia care. It can also be used to identify ethical issues that should be \naddressed in d ementia -specific training programmes, national strategy plans and clinical practice guidelines. \nFurther research should evaluate whether this new genre of systematic reviews can be applied to the identification \nof ethical issues in other cognitive and soma tic diseases. Also, the practical challenges in addressing ethical issues \nin training material, guidelines and policies need to be evaluated.  \nS23587564  \nThis study is the first to explore the benefit of treating asymptomatic or mildly symptomatic men with a n enlarged \nprostate. Dutasteride significantly decreased the incidence of benign prostatic hyperplasia clinical progression.  \nS23645857  \nThe application of age adjusted cut -off values for D -dimer tests substantially increases specificity without modifying \nsensitivity, thereby improving the clinical utility of D -dimer testing in patients aged 50 or more with a non -high clinical \nprobability.  \nS23694687  \nThe increased incidence of cancer after CT scan exposure in this cohort was mostly due to irradiation. Because the \ncancer excess was still continuing at the end of follow -up, the eventual lifetime risk from CT scans cannot yet be \ndetermined. Radiation doses from contemporary CT scans are likely to be lower than those in 1985 -2005, but some \nincrease in cancer risk i s still likely from current scans. Future CT scans should be limited to situations where there \nis a definite clinical indication, with every scan optimised to provide a diagnostic CT image at the lowest possible \nradiation dose.  \nS23618722  \nSitagliptin use wa s not associated with an excess risk of all cause hospital admission or death compared with other \nglucose lowering agents among newly treated patients with type 2 diabetes. Most patients prescribed sitagliptin in \nthis cohort were concordant with clinical p ractice guidelines, in that it was used as add -on treatment.  \nS23637132  \nThe research published to date suggests that cosmetic breast augmentation adversely affects the survival of \nwomen who are subsequently diagnosed as having breast cancer. These findings should be interpreted with \ncaution, as some studies included in the meta -analysis on survival did not adjust for potential confounders. Further \ninvestigations are warranted regarding diagnosis and prognosis of breast cancer among women with breast \nimplants . \nS23641033  \nQStroke provides a valid measure of absolute stroke risk in the general population of patients free of stroke or \ntransient ischaemic attack as shown by its performance in a separate validation cohort. QStroke also shows some \nimprovement on curr ent risk scoring methods, CHADS2 and CHA2DS2VASc, for the subset of patients with atrial \nfibrillation for whom anticoagulation may be required. Further research is needed to evaluate the cost effectiveness \nof using these algorithms in primary care.  \nS237041 71 \nCompared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be \nassociated with an increased risk of new onset diabetes.  \nS23596126  \nMeasurement of PSA concentration in early midlife can identify a small  group of men at increased risk of prostate \ncancer metastasis several decades later. Careful surveillance is warranted in these men. Given existing data on the \nrisk of death by PSA concentration at age 60, these results suggest that three lifetime PSA test s (mid to late 40s, \nearly 50s, and 60) are probably sufficient for at least half of men.  \n \nConclusions Supported self monitoring by telemonitoring is an effective method for achieving clinically important \nreductions in blood pressure in patients with uncont rolled hypertension in primary care settings. However, it was \nassociated with increase in use of National Health Service resources. Further research is required to determine if \nthe reduction in blood pressure is maintained in the longer term and if the int ervention is cost effective.  \nS23633005  A clinical rule based on symptoms and signs to predict pneumonia in patients presenting to primary care with acute \ncough performed best in patients with mild or severe clinical presentation. Addition of CRP concentrat ion at the \noptimal cut off of >30 mg/L improved diagnostic information, but measurement of procalcitonin concentration did not \nadd clinically relevant information in this group.  \nS23674137  \nReductions in the rates of admissions to hospital for cycling relate d head injuries were greater in provinces with \nhelmet legislation, but injury rates were already decreasing before the implementation of legislation and the rate of \ndecline was not appreciably altered on introduction of legislation. While helmets reduce th e risk of head injuries and \nwe encourage their use, in the Canadian context of existing safety campaigns, improvements to the cycling \ninfrastructure, and the passive uptake of helmets, the incremental contribution of provincial helmet legislation to \nreduce  hospital admissions for head injuries seems to have been minimal.  \nS23670660  \nAn intervention to enhance self management support in routine primary care did not add noticeable value to existing \ncare for long term conditions. The active components required for effective self management support need to be \nbetter understood, both within primary care and in patients' everyday lives.  \n \nCANADIAN MEDICAL ASSOCIATION JOURNAL  \n \nS23549975  \nThere was no significant difference in the number of episodes of severe pharyngitis between the control and \ntreatment groups, and episodes were rare. However, tonsillectomy resulted in fewer symptoms of pharyngitis, \nconsequently decreasing the number of medical visits and days absent from school or work. For this reason, \nsurge ry may benefit some patients  \n \nCIRCULATION  \n \nS23575355  \nThe decision as to which calculator to use for risk estimation has an important impact on both risk categorization \nand absolute risk estimates. This has broad implications for guidelines recommending the rapies based on specific \ncalculators.  \n \nDIABETES CARE  \n \nS23340887  \nCVD risk factors are increased up to 30 years before diagnosis of diabetes. These findings highlight the importance \nof a life course approach to CVD risk factor identification among individual s at risk for diabetes.  \nS23230096  \nTreatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow -up of 5.0 \nyears compared with glipizide. Our results indicated a potential benefit of metformin  therapy on cardiovascular \noutcomes in high -risk patients.  \nS23248197  \nIn patients with T2DM and chronic renal insufficiency, sitagliptin and glipizide provided similar A1C -lowering \nefficacy. Sitagliptin was generally well -tolerated, with a lower risk of hyp oglycemia and weight loss versus weight \ngain, relative to glipizide.  \nS23359362  \nAggressive monitoring of CVD risk in diabetic patients with depressive symptoms or who are treated with ADM may \nbe warranted.  \nS23223405  \nA 4-year ILI increased fitness and PA in overweight/obese individuals with T2DM. Change in fitness was associated \nwith improvements in glycemic control, which provides support for interventions to improve fitness in adults with \nT2DM.  \nS23613602  \nOur meta -analysis showed an inverse and significant a ssociation between circulating 25(OH)D levels and risk of \ntype 2 diabetes across a broad range of blood 25(OH)D levels in diverse populations.  \nS23393216  \nVitamin D deficiency appears to be an independent risk factor for the development of IFG and diabetes.  \nS23238658  \nBoth the severity of retinopathy and its progression are determinants of incident CV outcomes. The retina may \nprovide an anatomical index of the effect of metabolic and hemodynamic factors on future CV outcomes.  \nS23248193  \nLonger duration of abdom inal obesity was associated with substantially higher risk for diabetes independent of the \ndegree of abdominal adiposity. Preventing or at least delaying the onset of abdominal obesity in young adulthood \nmay lower the risk of developing diabetes through mi ddle age.  \nS23704672  Prevalence of hypertension and microalbuminuria increased over time among adolescents with type 2 diabetes \nregardless of diabetes treatment. The greatest risk for hypertension was male sex and higher BMI. The risk for \nmicroalbuminuria w as more closely related to glycemic control.  \nS23248196  \nIn this sample of the general population, statin therapy was associated with 14% increased risk of type 2 diabetes. \nDifferential survival did not explain this increased risk.  \nS23275370  \nThe UKPDS -OM has  good predictive accuracy for two of four risk factor time paths and for 10 -year clinical outcome \nprobabilities with the exception of stroke, amputation, heart failure, and death from any cause. An updated version \nof the model incorporating PTM data is bei ng developed.  \nS23589542  \nThe workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of \nhypoglycemia on both short - and long -term outcomes, considered the implications of hypoglycemia on treatment \noutcomes, pres ented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed \nby future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document \ncounseling are provided.  \nS23230095  \nPCPs  provide better care through higher rates of medication intensification and lifestyle counseling. Covering \nphysicians and midlevel providers may enable more frequent encounters when PCP resources are constrained.  \nS23275365  \nDiabetes is associated with incre ased risk of peripheral neuropathy defined by monofilament insensitivity, but \nprediabetes and undiagnosed diabetes may be associated with only a modest increase in risk.  \nS23404305  \nThe risk engine accurately predicts macro - and microvascular complications a nd would provide helpful information \nin risk classification and health economic simulations.  \n \nDRUGS  \n \nS23677802  \nInhaled glycopyrronium bromide (Seebri(\u00ae) Breezhaler(\u00ae) capsules; NVA237) is a once -daily, long -acting \nmuscarinic  receptor antagonist (LAMA) that is approved in several countries, including the EU, as a maintenance \nbronchodilator for the symptomatic treatment of adult patients with chronic obstructive pulmonary disease (COPD). \nIn the randomized, controlled, phase III  GLOW (GLycopyrronium bromide in chronic Obstructive pulmonary disease \nairWays clinical study) -1 and -2 trials, treatment with inhaled glycopyrronium bromide 50 \u00b5g once daily was \nassociated with significantly better lung function than placebo in patients w ith moderate to severe COPD in terms of \nthe trough forced expiratory volume in one second (FEV1) at 12 weeks (primary endpoint). Significant between -\ngroup differences in trough FEV1 in favour of inhaled glycopyrronium bromide were maintained for up to 52 w eeks. \nDyspnoea scores, health status and exacerbation rates were also improved to a greater extent in the inhaled \nglycopyrronium bromide than placebo groups in these trials. In the randomized, controlled, phase III GLOW3 trial, \ninhaled glycopyrronium bromi de was associated with a significantly longer exercise endurance time than placebo \nafter 3 weeks' treatment in patients with moderate to severe COPD. The drug was generally well tolerated over the \n26-week (GLOW1) or 52 -week (GLOW2) study duration, and had a tolerability profile that was generally similar to \nthat of tiotropium bromide. Serious adverse events were consistent with those expected in patients with moderate to \nsevere COPD. In conclusion, inhaled glycopyrronium bromide is a once -daily LAMA that is  an effective \nbronchodilator for use in the treatment of patients with moderate to severe COPD.  \nS23620200  \nInsulin degludec (Tresiba(\u00ae)) is an ultra -long-acting insulin analogue that is also available as a coformulation with \nrapid -acting insulin aspart (in sulin degludec/insulin aspart) [Ryzodeg(\u00ae)]. Insulin degludec has a flat, stable glucose -\nlowering profile with a duration of action of >42 h, and less within -patient day -to-day variability in glucose -lowering \neffect than the long -acting insulin analogue in sulin glargine. In clinical trials, insulin degludec achieved similar \nglycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower risk of \nnocturnal hypoglycaemia. In addition, trials examining a flexible dos ing regimen of insulin degludec in patients with \ntype 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or \nsafety. A 200 U/mL formulation of insulin degludec is also available for use in patients wh o require large volumes of \nbasal insulin. Insulin degludec/insulin aspart was noninferior to the long -acting insulin analogue insulin detemir in \npatients with type 1 diabetes and has the potential to reduce the number of daily injections. Trial results als o \nindicate that insulin degludec/insulin aspart may be an appropriate option for initiating insulin therapy in patients with \ntype 2 diabetes inadequately controlled with oral antidiabetic drugs. Subcutaneous insulin degludec was generally \nwell tolerated in  patients with type 1 or 2 diabetes. In conclusion, insulin degludec and insulin degludec/insulin \naspart represent a useful advance in the treatment of type 1 or 2 diabetes.  \nS23677801  \nRivaroxaban (Xarelto(\u00ae)), a direct factor Xa inhibitor, is approved for  the prevention of stroke and systemic \nembolism in patients with atrial fibrillation (AF) in Canada or those with nonvalvular AF (NVAF) in the EU, US and \nJapan. It is administered at a fixed oral dose and generally does not require routine monitoring of co agulation \nparameters. In the ROCKET AF trial in patients with NVAF and a moderate to high risk of stroke, oral rivaroxaban 20 mg once daily (15 mg once daily in patients with moderate renal impairment) was noninferior to oral dose -\nadjusted warfarin once da ily in preventing primary endpoint events (i.e. stroke and systemic embolism) in the per -\nprotocol population (primary noninferiority analysis) and superior in the on -treatment safety population (primary \nsuperiority analysis). Several ROCKET AF subgroup ana lyses indicated that the treatment effect of rivaroxaban was \nconsistent across patient subgroups stratified according to baseline factors, including the presence or absence of \nprevious stroke or transient ischaemic attack. Patients with moderate renal impa irment receiving the reduced \nrivaroxaban dosage (15 mg once daily) showed a treatment effect consistent with that seen with rivaroxaban 20 mg \nonce daily in patients with normal renal function. The tolerability profile of rivaroxaban was generally acceptabl e in \nROCKET AF, with no significant difference between rivaroxaban and warfarin in the incidence of major or nonmajor \nclinically -relevant bleeding events (primary safety endpoint). In the Japanese ROCKET AF trial, rivaroxaban 15 mg \nonce daily (10 mg once d aily in patients with moderate renal impairment) was noninferior to oral dose -adjusted \nwarfarin once daily in the incidence of major or nonmajor clinically -relevant bleeding (primary study outcome). Thus, \nrivaroxaban is a reasonable alternative to warfarin  for the prevention of stroke and systemic embolism in patients \nwith NVAF.  \n \n \nEUROPEAN HEART JOURNAL  \n \nS23186806  \nDigoxin was associated with a significant increase in all -cause mortality in patients with AF after correcting for \nclinical characteristics and comorbidities, regardless of gender or of the presence or absence of HF. These findings \ncall into question the widespread use of digoxin in patients with AF.  \nS23592708  \nIn patients with paroxysmal and persistent AF, we found no evidence of increased mortali ty or hospitalization in \nthose taking digoxin as baseline initial therapy.  \nS23095984  \nIn patients with HF of both reduced and preserved EF, the influences of readily available predictors of mortality can \nbe quantified in an integer score accessible by an ea sy-to-use website www.heartfailurerisk.org. The score has the \npotential for widespread implementation in a clinical setting.  \nS23257953  \nDespite strong inverse and apparently independent associations of 25(OH)D with vascular and non -vascular \nmortality, causa lity remains uncertain. Large -scale randomized trials, using high doses of vitamin D, are required to \nassess the clinical relevance of these associations.  \nS23315905  \nDeficient 25(OH)D levels are prevalent in cardiac surgical patients in Central Europe and a re independently \nassociated with the risk of MACCE. Further research should clarify the potential of vitamin D supplements in \nreducing cardiovascular risk in vitamin D -deficient patients and also the mechanisms leading to adverse effects on \nthe cardiovascu lar system in the small group of patients with 25(OH)D levels >100 nmol/L.  \nS23487517  \nBetrixaban was well tolerated and had similar or lower rates of bleeding compared with well -controlled warfarin in \npatients with AF at risk for stroke.  \nS23386711  \nAssessment of atrial fibrillation (AF) -associated stroke risk is at present mainly based on clinical risk scores such as \nCHADS2 and CHA2DS2 -VASc, although these scores provide only modest discrimination of risk for individual \npatients. Biomarkers derived f rom the blood may help refine risk assessment in AF for stroke outcomes and for \nmortality. Recent studies of biomarkers in AF have shown that they can substantially improve risk stratification. \nCardiac biomarkers, such as troponin and natriuretic peptides,  significantly improve risk stratification in addition to \ncurrent clinical risk stratification models. Similar findings have recently been described for markers of renal function, \ncoagulation, and inflammation in AF populations based on large randomized pr ospective clinical trials or large \ncommunity -based cohorts. These new findings may enable development of novel tools to improve clinical risk \nassessment in AF. Biomarkers in AF may also improve the understanding of the pathophysiology of AF further as \nwell as potentially elucidate novel treatment targets. This review will highlight novel associations of biomarkers and \noutcomes in AF as well as recent progress in the use of biomarkers for risk stratification.  \nS23449857  \nIn this European cohort, JUPITER -eligib le individuals had significantly higher event rates compared with those with \nLDL-C <3.4 mmol/L/C -reactive protein <2 mg and LDL -C \u22653.4 mmol/L/C -reactive protein <2 mg/L. Application of the \nJUPITER criteria qualified almost one -fifth of the population for s tatin therapy that otherwise would not have \nqualified based on SCORE or ATP III criteria.  \n \nFAMILY MEDICINE  \n \nS23681682  \nPatients with diabetes regularly discussed self -care activities during follow -up visits at family medicine clinics. \nProviders varied in t heir capacity to incorporate self -care planning into routine medical care for patients with diabetes. Interventions are needed that help improve goal -setting and documentation. Documentation of self -care \ndiscussions will be important for meeting Meaningful  Use criteria.  \nS23681681  \nFamily physicians perceived that their approaches to patient care result in medical decision making priorities and \ncare delivery processes that contribute to more cost -effective health care. These outcomes were achieved less by \nproviding preventive services and strictly adhering to guidelines but rather by how they individualized the \nmanagement of new symptoms and chronic conditions.  \nS23681686  \nIn 2010, six ministries of the Chinese government jointly issued a plan for building team -based primary care led by \nfamily physicians, prompting the creation of new models of family medicine training across the country. The purpose \nof this paper is to desc ribe examples of existing family physician training models in China, to present advantages \nand disadvantages of the various models, and to present a specific model of family medicine residency training \nimplemented at the Zhejiang University Medical School -affiliated Sir Run Run Shaw Hospital in collaboration with \nthe Michigan State University -affiliated Genesys Regional Medical Center.  \n \nGACETA SANITARIA  \n \nS22840438  \nLos usuarios perciben una continuidad asistencial, aunque identifican elementos de discontinuidad, explicados \nparcialmente por el \u00e1rea de salud y por algunos factores individuales. Su abordaje contribuir\u00eda a adecuar la \natenci\u00f3n a las necesidades de los pacientes.  \nS23207428  \nLa innovaci\u00f3n del estudio AMIEHS es una aproximaci\u00f3n rigurosa a la nueva concepci\u00f3n de la mortalidad tratable \nque incluye validaci\u00f3n emp\u00edrica. Para evaluar la calidad de los sistemas de salud en comparaci\u00f3n con otros pa\u00edses \ns\u00f3lo pueden usarse con \u00e9xito indicadores validados.  \nS23103093  \nLa versi\u00f3n corta del Cuestionario  Internacional de Actividad F\u00edsica en su adaptaci\u00f3n al catal\u00e1n muestra una validez \naceptable para medir la actividad f\u00edsica total y el tiempo dedicado a realizar actividad f\u00edsica vigorosa. Puede \nutilizarse para medir la adherencia a las recomendaciones de actividad f\u00edsica en la poblaci\u00f3n catalana.  \nS23291031  \nEste estudio corrobora la estratificaci\u00f3n social de la funcionalidad y de la muerte, sugiriendo que la edad no es un \nnivelador. En Latinoam\u00e9rica, las pol\u00edticas sociales deber\u00edan orientarse a reducir est as desigualdades, buscando \nprevenir la exposici\u00f3n a riesgos y compensar carencias (en particular entre los m\u00e1s pobres) para minimizar la \ntransformaci\u00f3n de un impedimento en limitaci\u00f3n y de una limitaci\u00f3n en discapacidad.  \nS23140979  \nLa evoluci\u00f3n de la canti dad y de la calidad de los servicios sanitarios que consume cada persona es un factor \nimportante en la evoluci\u00f3n del gasto sanitario, que es necesario introducir en el c\u00e1lculo de proyecciones.  \nS22981418  \nLos usuarios perciben una continuidad asistencial, a unque identifican elementos de discontinuidad, explicados \nparcialmente por el \u00e1rea de salud y por algunos factores individuales. Su abordaje contribuir\u00eda a adecuar la \natenci\u00f3n a las necesidades de los pacientes.  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nS23644932  \nAddition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not further \nreduce risk of progression to advanced AMD. However, because of potential increased incidence of lung cancer in \nformer smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.  \n \nJAMA INTERNAL MEDICINE  \n \nS23460413  \nThe risk for hip fracture is elevated among nursing home residents using a nonbenzodiazepine hypnotic drug. New \nusers and reside nts having mild to moderate cognitive impairment or requiring limited assistance with transfers may \nbe most vulnerable to the use of these drugs. Caution should be exercised when prescribing sleep medications to \nnursing home residents.  \nS23552817  \nWomen age d 50 to 74 years, even those with high breast density or HT use, who undergo biennial screening \nmammography have similar risk of advanced -stage disease and lower cumulative risk of false -positive results than \nthose who undergo annual mammography. When deci ding whether to undergo mammography, women aged 40 to \n49 years who have extremely dense breasts should be informed that annual mammography may minimize their risk \nof advanced -stage disease but the cumulative risk of false -positive results is high  \nS23545598  \nIn inactive older adults with cognitive complaints, 12 weeks of physical plus mental activity was associated with \nsignificant improvements in global cognitive function with no evidence of difference between intervention and active control groups . These findings may reflect practice effects or may suggest that the amount of activity is more \nimportant than the type in this subject population. TRIAL REGISTRATION clinicaltrials.gov Identifier:NCT00522899.  \n \nJAMA PSYCHIATRY  \n \nS23536105  \nIn a community s ample, varenicline exerts a robust and favorable effect on smoking cessation relative to placebo \nand may have a favorable (suppressive) effect on symptoms of depression and other affective measures, with no \nclear unfavorable effect on neuropsychiatric adve rse events.  \n \n \nMEDICINA CLINICA  \n \nS22578993  \nLa aplicaci\u00f3n de una propuesta de criterios de indicaci\u00f3n de densitometr\u00eda \u00f3sea en mujeres posmenop\u00e1usicas  \nbasada en la edad y en el riesgo de fractura calculado por FRAX\u00ae tendr\u00eda como consecuencia una disminuci\u00f3n \nsignificativa de la actividad de la unidad de densitometr\u00eda \u00f3sea.  \nS23177315  \nEn este art\u00edculo se realiza una revisi\u00f3n general de los diferentes proc edimientos intervencionistas percut\u00e1neos, \nguiados mediante t\u00e9cnicas de imagen, y utilizados para el diagn\u00f3stico y tratamiento de las diversas causas \nresponsables del dolor de raquis. Estos procedimientos pueden ser meramente diagn\u00f3sticos, como la discograf \u00eda y \nla biopsia, diagn\u00f3sticos y terap\u00e9uticos, como las infiltraciones, o puramente terap\u00e9uticos, como la vertebroplastia, \nlas t\u00e9cnicas descompresivas del disco intervertebral o la ablaci\u00f3n tumoral. Se revisan las indicaciones, ventajas y \ncomplicaciones de las diferentes t\u00e9cnicas.  \nS23337456  \nEn pacientes con ICA los valores elevados del ADE se asocian a una mayor mortalidad a largo plazo.  \n \nTHE NEW ENGLAND JOURNAL OF MEDICINE  \n \nS23577628  \nNovel reassortant  H7N9 viruses were associated with severe and fatal respiratory disease in three patients  \nS23675658  \nCurrent policy recommendations that are aimed at expanding the supply and scope of practice of primary care \nnurse practitioners are controversial. Physicia ns and nurse practitioners do not agree about their respective roles in \nthe delivery of primary care  \n \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}